University of California San Francisco

Mehta
Neil
Mehta
MD

Associate Professor of Medicine

General Hepatology and Liver Transplantation

Department of Medicine

Address

400 Parnassus Avenue, #A740
San Francisco, CA 94117
United States

Phone: 415-502-2569
Fax: 415-476-0659

Biography

Dr. Neil Mehta is a gastroenterologist and specialist in liver transplantation.

In his research, Mehta examines liver cancer treatment, particularly as related to liver transplants. He has contributed to important publications in this area. His other research interests include outcomes for patients who undergo liver transplantation and cardiac iron overload in patients with chronic liver disease. He frequently lectures in the community and at the university on these subjects.

At the UCSF School of Medicine, Mehta supervises the training of residents as well as fellows in both gastroenterology and liver transplant medicine. He also delivers lectures on liver disease to UCSF medical students studying metabolism and nutrition.

Mehta earned his medical degree at UCSF and completed a residency in internal medicine at the University of Pennsylvania. He completed fellowships in gastroenterology and liver transplantation at UCSF.

Education

Institution Degree Dept or School End Date
University of California, San Francisco M.D. Medicine 2006

Board Certifications

American Board of Internal Medicine
American Board of Internal Medicine - Gastroenterology
American Board of Internal Medicine - Transplant Hepatology

Collaboration Interests

I am interested in:

  • PolicyChange

Clinical Expertise

Alcoholic Liver Disease

Autoimmune Hepatitis

Cirrhosis

Drug-Induced Hepatitis

Fulminant Hepatic Failure

Hemochromatosis

Hepatitis B

Hepatitis C

Hepatocellular Carcinoma (Liver Cancer)

Liver Transplantation

Living Donor Liver Transplantation

Nonalcoholic Fatty Liver Disease

Polycystic Liver Disease

Primary Biliary Cirrhosis

Primary Sclerosing Cholangitis

Clinical Trials

  1. National Liver Cancer Screening Trial (NCT06084234)
    Related Conditions: Liver Cancer, Cirrhosis, Hepatitis B, Cancer, General, Hepatocellular Cancer| Start Date: | End Date:

Program Affiliations

UCSF Liver Center

In the News

Mignote Yilma, M.D. to Join National Clinician Scholars Program at UCSF
December, 16, 2020 | UCSF General Surgery Residency Program
Study Shows Excellent Post-Transplant Outcomes Following Down-Staging of HCC Patients
December, 10, 2014 | UCSF Transplant Surgery

Research Narrative

Dr. Mehta is engaged in research investigating clinical outcomes in patients with end-stage liver disease. His research focuses on two main areas:

  • Understanding issues related to the diagnosis and management of patients with hepatocellular carcinoma (HCC) particularly with regards to outcomes in liver transplantation. Specific topics we are currently interested in are evaluating the risk of HCC recurrence post-transplant based on transplant waiting times, creating an HCC recurrence risk score, and downstaging tumors in to conventional transplant criteria.
  • Understanding the role of iron overload in patients listed for liver transplant, specifically with regards to both hepatic and cardiac iron deposition.

Mr. Mehta is also conducting research related to the diagnosis and management of patients with hepatocellular carcinoma (HCC) particularly with regards to outcomes in liver transplantation.This includes a multicenter project with CPMC and Scripps to understand the role of downstaging tumors into conventional transplant criteria. He is also pursuing projects to address the risk of HCC recurrence post-transplant based on transplant waiting times as well as to create an HCC recurrence risk score. These projects are being done collaboratively with the Mayo clinic in Rochester and Jacksonville.

Dr. Mehta is also pursuing research to help optimize the management of iron overload in patients listed for liver transplant, specifically with regards to both hepatic and cardiac iron deposition.

Research Interests

Hepatocellular carcinoma (HCC)

Liver transplantation outcomes including expanded criteria liver transplants

Cardiopulmonary complications of chronic liver disease

Liver injury and repair (Liver transplantation)

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 171
  1. Development and validation of a biomarker index for HCC treatment response.
    Liang J, Li PY, Norman J, Lauzon M, Yeo YH, Trivedi H, Ayoub WS, Kuo A, Friedman ML, Sankar K, Gong J, Osipov A, Hendifar A, Todo T, Kim I, Voidonikolas G, Brennan TV, Wisel SA, Steggarda J, Kosari K, Saouaf R, Nissen N, Yao F, Mehta N, Yang JD| | View in PubMed
  2. Bridging the rural-urban gap in access to liver transplantation.
    Zhou K, Shah S, Thompson LK, Mehta N| | View in PubMed
  3. Immunotherapy for hepatocellular carcinoma: the next evolution in expanding access to liver transplantation.
    Li M, Bhoori S, Mehta N, Mazzaferro V| | View in PubMed
  4. Role of biomarkers in the diagnosis and management of HCC.
    Al-Hasan M, Mehta N, Yang JD, Singal AG| | View in PubMed
  5. Barriers to liver transplant referral in safety net settings: A national provider survey.
    Hundt M, Chen A, Donovan J, Kim N, Yilma M, Tana M, Mehta N, Zhou K| | View in PubMed
  6. Updates in liver transplantation policy for patients with hepatocellular carcinoma (HCC).
    Mehta N| | View in PubMed
  7. Abstract No. 158 Cost-Effectiveness Analysis of Resection, Ablation, and Radiation Segmentectomy for Solitary Hepatocellular Carcinoma = 3 cm with Curative Intent.
    X. Wu, P. Vakil, M. Heller, E. Lehrman, N. Fidelman, N. Mehta, R. Lokken| | View in PubMed
  8. Immune checkpoint inhibitors in liver transplantation: Current practice, challenges, and opportunities.
    Martin SP, Mehta N, Emamaullee J| | View in PubMed
  9. Reply to: "Enhancing HCC recurrence prediction after liver transplantation: From DCP plus AFP-L3 model to GALAD score".
    Norman JS, Mehta N| | View in PubMed
  10. Reply to: "Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: What are the optimal criteria?"
    Norman JS, Mehta N| | View in PubMed
  11. Neighborhood-level Social Determinants of Health and Waitlist Mortality for Liver Transplantation: The Liver Outcomes and Equity Index.
    Zhou K, Lit A, Kuo LS, Thompson LK, Dodge JL, Mehta N, Terrault NA, Ha NB, Cockburn MG| | View in PubMed
  12. Per-patient Negative Predictive Value of the CT and MRI Liver Imaging Reporting and Data System Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma.
    Hassan OT, Behr SC, Ohliger MA, Fowler KJ, Gill RM, Fidelman N, Mehta N, Choi HH| | View in PubMed
  13. How I Approach Hepatocellular Adenomas in Hormonally Distinct Populations: Time to Think Outside the (Contraceptive Pill) Box.
    Wang M, Cedars MI, Mehta N, Sarkar M| | View in PubMed
  14. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation.
    Norman JS, Li PJ, Kotwani P, Shui AM, Yao F, Mehta N| | View in PubMed
  15. Cost-effectiveness analysis of interventional liver-directed therapies for downstaging of HCC before liver transplant.
    Wu X, Kwong A, Heller M, Lokken RP, Fidelman N, Mehta N| | View in PubMed
  16. Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma.
    Yilma M, Mehta N| | View in PubMed
  17. Downstaging hepatocellular carcinoma before liver transplantation: A multicenter analysis of the "all-comers" protocol in the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortium.
    Natarajan B, Tabrizian P, Hoteit M, Frenette C, Parikh N, Ghaziani T, Dhanasekaran R, Guy J, Shui A, Florman S, Yao FY, Mehta N| | View in PubMed
  18. Living Donor Liver Transplantation for Hepatocellular Carcinoma Within and Outside Traditional Selection Criteria: A Multicentric North American Experience.
    Ivanics T, Claasen MPAW, Samstein B, Emond JC, Fox AN, Pomfret E, Pomposelli J, Tabrizian P, Florman SS, Mehta N, Roberts JP, Emamaullee JA, Genyk Y, Hernandez-Alejandro R, Tomiyama K, Sasaki K, Hashimoto K, Nagai S, Abouljoud M, Olthoff KM, Hoteit MA, Heimbach J, Taner T, Liapakis AH, Mulligan DC, Sapisochin G, Halazun KJ, North American Living Liver Donor Innovation Group (NALLDIG)| | View in PubMed
  19. Community-level social vulnerability and individual socioeconomic status on liver transplant referral outcome.
    Yilma M, Cogan R, Shui AM, Neuhaus JM, Light C, Braun H, Mehta N, Hirose R| | View in PubMed
  20. Optimizing liver transplant prioritization for hepatocellular carcinoma through risk stratification.
    Norman J, Mehta N, Kwong A| | View in PubMed
  21. Factors Associated With Liver Transplant Referral Among Patients With Cirrhosis at Multiple Safety-Net Hospitals.
    Yilma M, Kim NJ, Shui AM, Tana M, Landis C, Chen A, Bangaru S, Mehta N, Zhou K| | View in PubMed
  22. Geographic disparities in access to liver transplantation.
    Yilma M, Dalal N, Wadhwani SI, Hirose R, Mehta N| | View in PubMed
  23. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.
    Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, Jou JH, Kulik LM, Agopian VG, Marrero JA, Mendiratta-Lala M, Brown DB, Rilling WS, Goyal L, Wei AC, Taddei TH| | View in PubMed
  24. Refining the approach to down-staging of HCC prior to liver transplantation: Patient selection, loco-regional treatments, and systemic therapies.
    Mehta N, Kelley RK, Yao FY| | View in PubMed
  25. Tu1550 UTILITY OF A BIOMARKER-DERIVED SCORE FOR TREATMENT RESPONSE ASSESSMENT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA.
    Jeff Liang, Po-Yi Li, Joshua S. Norman, Yee Hui Yeo, Hirsh D. Trivedi, Walid S. Ayoub, Alexander Kuo, Marc L. Friedman, Tsuyoshi Todo, Irene Kim, Georgios Voidonikolas, Todd Brennan, Steven Wisel, Kambiz Kosari, Rola Saouaf, Nicholas N. Nissen, Neil Mehta, Ju Dong Yang| | View in PubMed
  26. AFP-L3 and DCP are superior to AFP in predicting waitlist dropout in HCC patients: Results of a prospective study.
    Mehta N, Kotwani P, Norman J, Shui A, Li PJ, Saxena V, Chan W, Yao FY| | View in PubMed
  27. Optimal treatment for small HCC (<3 cm): Resection, liver transplantation, or locoregional therapy?
    Wu X, Lokken RP, Mehta N| | View in PubMed
  28. Resected Tumor Outcome and Recurrence (RESTORE) Index for Hepatocellular Carcinoma Recurrence after Resection.
    Hoffman D, Shui A, Gill R, Syed S, Mehta N| | View in PubMed
  29. Patient survey augments detection of harmful alcohol relapse after liver transplant for alcohol-associated cirrhosis.
    Rice BA, Mehta N, Grab J, Dodge JL, Sherman CB| | View in PubMed
  30. Abstract No. 251 ? FEATURED ABSTRACT Cost-Effectiveness Analysis of Interventional Liver-Directed Therapies for Downstaging of Hepatocellular Carcinoma Before Liver Transplant.
    X. Wu, A. Kwong, M. Heller, R. Lokken, N. Fidelman, N. Mehta| | View in PubMed
  31. Recall patterns and risk of primary liver cancer for subcentimeter ultrasound liver observations: a multicenter study.
    Singal AG, Ghaziani TT, Mehta N, Zhou K, Grinspan LT, Benhammou JN, Moon AM, Yang JD, Salgia R, Pillai A, Zheng E, Rich NE, Gopal P, Jalal P, Verna E, Yekkaluri S, Phen S, Melendez-Torres J, Alshuwaykh O, Choi H, Junus K, Grady J, Song M, Leven EA, Yum J, Gowda V, Alsudaney M, Hernandez P, Desai N, Parikh ND| | View in PubMed
  32. Cost-Effectiveness Analysis of Interventional Liver-Directed Therapies for a Single, Small Hepatocellular Carcinoma in Liver Transplant Candidates.
    Wu X, Heller M, Kwong A, Fidelman N, Mehta N| | View in PubMed
  33. Outcomes after liver transplantation using deceased after circulatory death donors: A comparison of outcomes in the UK and the US.
    Ivanics T, Claasen MPAW, Patel MS, Giorgakis E, Khorsandi SE, Srinivasan P, Prachalias A, Menon K, Jassem W, Cortes M, Sayed BA, Mathur AK, Walker K, Taylor R, Heaton N, Mehta N, Segev DL, Massie AB, van der Meulen JHP, Sapisochin G, Wallace D| | View in PubMed
  34. Number of Local Regional Therapies for Hepatocellular Carcinoma and Peri-Operative Outcomes after Liver Transplantation.
    Brown AE, Shui AM, Adelmann D, Mehta N, Roll GR, Hirose R, Syed SM| | View in PubMed
  35. Alpha-fetoprotein slope over 7.5 ng/ml over 3 months before liver transplantation for hepatocellular carcinoma predicts recurrence even after controlling for alpha-fetoprotein at liver transplantation.
    Giard JM, Dodge JL, Yao FY, Mehta N| | View in PubMed
  36. Influence of progestin-only hormonal use on hepatocellular adenomas: A retrospective cohort study.
    Qureshy Z, Lokken RP, Kakar S, Grab J, Mehta N, Sarkar M| | View in PubMed
  37. An Open-Access, Interactive Decision-Support Tool to Facilitate Guideline-Driven Care for Hepatocellular Carcinoma.
    Wong RJ, Jayasekera C, Jones P, Kanwal F, Singal AG, Ahmed A, Taglienti R, Younossi Z, Kulik L, Mehta N| | View in PubMed
  38. Now you see it, now you don't: Estrogen exposure and obesity effects on HCA development and regression.
    Wang M, Sarkar M, Mehta N| | View in PubMed
  39. Low utilization of adult-to-adult LDLT in Western countries despite excellent outcomes: International multicenter analysis of the US, the UK, and Canada.
    Ivanics T, Wallace D, Claasen MPAW, Patel MS, Brahmbhatt R, Shwaartz C, Prachalias A, Srinivasan P, Jassem W, Heaton N, Cattral MS, Selzner N, Ghanekar A, Morgenshtern G, Mehta N, Massie AB, van der Meulen J, Segev DL, Sapisochin G| | View in PubMed
  40. Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma.
    Tabrizian P, Holzner ML, Mehta N, Halazun K, Agopian VG, Yao F, Busuttil RW, Roberts J, Emond JC, Samstein B, Brown RS, Najjar M, Chapman WC, Doyle MM, Florman SS, Schwartz ME, Llovet JM| | View in PubMed
  41. National Experience on Waitlist Outcomes for Down-Staging of Hepatocellular Carcinoma: High Dropout Rate in All-Comers.
    Huang AC, Dodge JL, Yao FY, Mehta N| | View in PubMed
  42. Liver allocation policies for hepatocellular carcinoma have leveled the playing field-But who should be playing?
    Kwong AJ, Mehta N| | View in PubMed
  43. Awarding additional MELD points to the shortest waitlist candidates improves sex disparity in access to liver transplant in the United States.
    Bernards S, Lee E, Leung N, Akan M, Gan K, Zhao H, Sarkar M, Tayur S, Mehta N| | View in PubMed
  44. Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma.
    Parikh ND, Mehta N, Hoteit MA, Yang JD, John BV, Moon AM, Salgia RJ, Pillai A, Kassab I, Saeed N, Thyssen E, Nathani P, McKinney J, Chan W, Durkin C, Connor M, Alsudaney M, Konjeti R, Durand B, Nissen NN, Kim HP, Paknikar R, Rich NE, Schipper MJ, Singal AG| | View in PubMed
  45. Abstract No. 261 Cost-effectiveness analysis of interventional liver-directed therapies for a single, small (< 3 cm) hepatocellular carcinoma in liver transplant candidates.
    X. Wu, M. Heller, A. Kwong, N. Fidelman, N. Mehta| | View in PubMed
  46. Nodular Regenerative Hyperplasia After Liver Transplant; It's All in the Presentation.
    Chen AK, Lunow-Luke T, Yamaguchi S, Praglin C, Agudelo E, Mehta N, Dirks R, Braun HJ, Gardner JM, Roberts JP, Syed SM, Roll GR| | View in PubMed
  47. 531: DEVELOPMENT AND VALIDATION OF A RISK SCORE FOR PREDICTING HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B WITHIN A LARGE, REPRESENTATIVE, NORTHERN CALIFORNIA COHORT.
    Varun Saxena, Liyan Liu, Joanna B. Ready, Mai Sedki, Krisna P. Chai, Suk I. Seo, Nizar A. Mukhtar, Sreepriya Balasubramanian, Brock A. Macdonald, Neil Mehta, Julie A. Schmittdiel| | View in PubMed
  48. EP1003: EVALUATION OF SOCIOECONOMIC STATUS WITHIN HOTSPOTS OF HEPATOCELLULAR CARCINOMA AMONG A LARGE DIVERSE PATIENT COHORT IN NORTHERN CALIFORNIA.
    Mignote Yilma, Jackson Voelkel, Richie Houhong Xu, Leu-Yen Tucker, Monica Muzzin, Varun Saxena, Neil Mehta, Jeffrey K. Lee, Suk I. Seo, Brock A. Macdonald, Joanna B. Ready, Sreepriya Balasubramanian, Nizar A. Mukhtar| | View in PubMed
  49. National experience with living donor liver transplantation for hepatocellular carcinoma.
    Silverstein J, Yao FY, Grab JD, Braun HJ, Roberts J, Dodge JL, Mehta N| | View in PubMed
  50. Machine learning to predict waitlist dropout among liver transplant candidates with hepatocellular carcinoma.
    Kwong A, Hameed B, Syed S, Ho R, Mard H, Arshad S, Ho I, Suleman T, Yao F, Mehta N| | View in PubMed
  51. Lower Alpha-Fetoprotein Threshold of 500 ng/mL for Liver Transplantation May Improve Posttransplant Outcomes in Patients With Hepatocellular Carcinoma.
    Goldman ML, Zhou K, Dodge JL, Yao F, Mehta N| | View in PubMed
  52. Models to Predict Development or Recurence of Hepatocellular Carcinoma (HCC) in Patients with Advanced Hepatic Fibrosis.
    Yilma M, Saxena V, Mehta N| | View in PubMed
  53. Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.
    Asrani SK, Ghabril MS, Kuo A, Merriman RB, Morgan T, Parikh ND, Ovchinsky N, Kanwal F, Volk ML, Ho C, Serper M, Mehta S, Agopian V, Cabrera R, Chernyak V, El-Serag HB, Heimbach J, Ioannou GN, Kaplan D, Marrero J, Mehta N, Singal A, Salem R, Taddei T, Walling AM, Tapper EB| | View in PubMed
  54. National time trends in mortality and graft survival following liver transplantation from circulatory death or brainstem death donors.
    Wallace D, Cowling TE, Suddle A, Gimson A, Rowe I, Callaghan C, Sapisochin G, Ivanics T, Claasen M, Mehta N, Heaton N, van der Meulen J, Walker K| | View in PubMed
  55. Decreased Urgency Among Liver Transplantation Candidates With Hepatocellular Carcinoma in the United States.
    Kwong AJ, Ghaziani TT, Mehta N| | View in PubMed
  56. The Impact of Median Model for End-Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma.
    Bernards S, Hirose R, Yao FY, Jin C, Dodge JL, Huang CY, Mehta N| | View in PubMed
  57. Survival After Liver Transplantation: An International Comparison Between the United States and the United Kingdom in the Years 2008-2016.
    Ivanics T, Wallace D, Abreu P, Claasen MPAW, Callaghan C, Cowling T, Walker K, Heaton N, Mehta N, Sapisochin G, van der Meulen J| | View in PubMed
  58. Sex-based Disparities in Hepatocellular Carcinoma Recurrence After Liver Transplantation.
    Cullaro G, Rubin J, Mehta N, Yao F, Verna EC, Lai JC| | View in PubMed
  59. Liver Transplantation After Downstaging of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Using Yttrium-90 Radioembolization: Pipe Dream or Reality?
    Mehta N, Yao FY| | View in PubMed
  60. Liver transplantation for HCC: validation of prognostic power of the RETREAT score for recurrence in a UK cohort.
    Reddy SHS, Mehta N, Dodge JL, Hakeem AR, Khorsandi SE, Jassem W, Vilca-Melendez H, Cortes-Cerisuelo M, Srinivasan P, Prachalias A, Heneghan MA, Aluvihare V, Suddle A, Miquel R, Rela M, Heaton ND, Menon KV| | View in PubMed
  61. National Trends and Waitlist Outcomes of Locoregional Therapy Among Liver Transplant Candidates With Hepatocellular Carcinoma in the United States.
    Kwong AJ, Ghaziani TT, Yao F, Sze D, Mannalithara A, Mehta N| | View in PubMed
  62. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium.
    Mehta N, Frenette C, Tabrizian P, Hoteit M, Guy J, Parikh N, Ghaziani TT, Dhanasekaran R, Dodge JL, Natarajan B, Holzner ML, Frankul L, Chan W, Fobar A, Florman S, Yao FY| | View in PubMed
  63. Liver Transplantation Criteria for Hepatocellular Carcinoma, Including Posttransplant Management.
    Mehta N| | View in PubMed
  64. Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma.
    Halazun KJ, Rosenblatt RE, Mehta N, Lai Q, Hajifathalian K, Gorgen A, Brar G, Sasaki K, Doyle MBM, Tabrizian P, Agopian VG, Najjar M, Ivanics T, Samstein B, Brown RS, Emond JC, Yao F, Lerut J, Rossi M, Mennini G, Iesari S, Finkenstedt A, Schaefer B, Mittler J, Hoppe-Lotichius M, Quintini C, Aucejo F, Chapman W, Sapisochin G| | View in PubMed
  65. Neutrophil-to-Lymphocyte Ratio Predicts High-Risk Explant Features and Waitlist Survival But Is Not Independently Associated With Recurrence or Survival Following Liver Transplantation for Hepatocellular Carcinoma.
    Harding-Theobald E, Yao FYK, Mehta N| | View in PubMed
  66. 433 THE ASSOCIATION OF SUSTAINED VIROLOGIC RESPONSE ON TREATMENT OUTCOMES IN PATIENTS WITH HEPATOCELLULAR CARCINOMA WITH HEPATITIS C.
    Neehar D. Parikh, Neil Mehta, Maarouf Hoteit, Ju Dong Yang, Binu V. John, Andrew M. Moon, Reena Salgia, Anjana A. Pillai, Ihab Kassab, Naba Saeed, Emil Thyssen, Piyush Nithani, Jeffrey Mckinney, Wesley Chan, Claire Durkin, Matthew Connor, Manaf Alsudaney, Brenda Durand, Nicholas N. Nissen, Hannah P. Kim, Raghavendra Paknikar, Nicole E. Rich, Matthew Schipper, Amit G. Singal| | View in PubMed
  67. Hepatic Toxicity After Selective Chemoembolization Is Associated With Decreased Survival Among Patients With Hepatocellular Carcinoma.
    Lokken RP, Kerlan RK, Chung YC, Chen YF, Mehta NJ, Yao FY, Fidelman N| | View in PubMed
  68. DCP and AFP-L3 Are Complementary to AFP in Predicting High-Risk Explant Features: Results of a Prospective Study.
    Kotwani P, Chan W, Yao F, Mehta N| | View in PubMed
  69. The Key Role of Staging Definitions for Assessment of Downstaging for Hepatocellular Carcinoma.
    Yao FY, Fidelman N, Mehta N| | View in PubMed
  70. Patterns of Alcohol Use After Early Liver Transplantation for Alcoholic Hepatitis.
    Lee BP, Im GY, Rice JP, Lazar A, Weinberg E, Han H, Maddur H, Ghobrial RM, Therapondos G, Hsu C, Fix OK, Eswaran S, Shetty K, Chhatwal J, Dalgic OO, Jakhete N, Mobley C, Victor DW, Mehta N, Dinges L, Rinella M, Schiano TD, Lucey MR, Terrault N| | View in PubMed
  71. Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers.
    Deng LX, Mehta N| | View in PubMed
  72. Reply.
    Mehta N, Yao FY| | View in PubMed
  73. Opioid use prior to liver transplant is associated with increased risk of death after transplant.
    Braun HJ, Schwab MP, Jin C, Amara D, Mehta NJ, Grace TR, Croci R, Freise CE, Roberts JP, Hirose R, Ascher NL| | View in PubMed
  74. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
    Mehta N, Dodge JL, Roberts JP, Yao FY| | View in PubMed
  75. Current Transplant Criteria for Hepatocellular Carcinoma—Overuse or Underuse.
    Varun Saxena, Neil Mehta| | View in PubMed
  76. COVID-19 and Abdominal Transplant: A Stepwise Approach to Practice During Pandemic Conditions.
    Syed SM, Gardner J, Roll G, Webber A, Mehta N, Shoji J, Adelmann D, Niemann C, Braun HJ, Mello A, Yao F, Posselt A, Kang SM, Hirose R, Roberts J, Feng S, Ascher N, Stock P, Freise C| | View in PubMed
  77. Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis.
    Rich NE, John BV, Parikh ND, Rowe I, Mehta N, Khatri G, Thomas SM, Anis M, Mendiratta-Lala M, Hernandez C, Odewole M, Sundaram LT, Konjeti VR, Shetty S, Shah T, Zhu H, Yopp AC, Hoshida Y, Yao FY, Marrero JA, Singal AG| | View in PubMed
  78. Social Media as an Early Proxy for Social Distancing Indicated by the COVID-19 Reproduction Number: Observational Study.
    Younis J, Freitag H, Ruthberg JS, Romanes JP, Nielsen C, Mehta N| | View in PubMed
  79. Expanding the Limits of Liver Transplantation for Hepatocellular Carcinoma: Is There a Limit?
    Kwong A, Mehta N| | View in PubMed
  80. Surveillance for HCC After Liver Transplantation: Increased Monitoring May Yield Aggressive Treatment Options and Improved Postrecurrence Survival.
    Lee DD, Sapisochin G, Mehta N, Gorgen A, Musto KR, Hajda H, Yao FY, Hodge DO, Carter RE, Harnois DM| | View in PubMed
  81. The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study.
    Gorgen A, Galvin Z, Huang AC, Vinaixa C, O'Rourke JM, Francoz C, Hansen BE, Durand F, Elsharkawy AM, Shah T, Berenguer M, Rubin A, Calatayud D, Mehta N, Terrault NA, Lilly LB, Selzner N, Sapisochin G| | View in PubMed
  82. Recurrence of hepatocellular carcinoma following liver transplantation.
    Hoffman D, Mehta N| | View in PubMed
  83. Effect of Nonalcoholic Fatty Liver Disease and Metabolic Risk Factors on Waitlist Outcomes in Patients With Hepatocellular Carcinoma.
    Weinfurtner K, Dodge JL, Yao FYK, Mehta N| | View in PubMed
  84. Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States.
    Kim NJ, Rozenberg-Ben-Dror K, Jacob DA, Rich NE, Singal AG, Aby ES, Yang JD, Nguyen V, Pillai A, Fuchs M, Moon AM, Shroff H, Agarwal PD, Perumalswami P, Chandna S, Zhou K, Patel YA, Latt NL, Wong R, Duarte-Rojo A, Lindenmeyer CC, Frenette C, Ge J, Mehta N, Yao F, Benhammou JN, Bloom PP, Leise M, Kim HS, Levy C, Barnard A, Khalili M, Ioannou GN| | View in PubMed
  85. Downstaging to Liver Transplant: Success Involves Choosing the Right Patient.
    Zhou K, Mehta N| | View in PubMed
  86. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).
    Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, Carmona-Rubio AE, Jacob M, Procop GW, Harrington S, Milinovich A, Svensson LG, Jehi L, Young JB, Chung MK| | View in PubMed
  87. OPIOID USE PRIOR TO LIVER TRANSPLANT IS ASSOCIATED WITH INCREASED RISK OF DEATH AFTER TRANSPLANT.
    Hillary Braun, Marisa P. Schwab, Chengshi Jin, Dominic Amara, Trevor Grace, Rhiannon Croci, Chris E. Freise, John P. Roberts, Neil Mehta, Ryutaro Hirose, Nancy L. Ascher| | View in PubMed
  88. Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin II Receptor Blockers: A Comparison of Outcomes in Patients With COVID-19.
    Kalra A, Hawkins ES, Nowacki AS, Jain V, Milinovich A, Saef J, Thomas G, Gebreselassie SK, Karnik SS, Jehi L, Young JB, Svensson LG, Chung MK, Mehta N| | View in PubMed
  89. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy.
    Chung MK, Karnik S, Saef J, Bergmann C, Barnard J, Lederman MM, Tilton J, Cheng F, Harding CV, Young JB, Mehta N, Cameron SJ, McCrae KR, Schmaier AH, Smith JD, Kalra A, Gebreselassie SK, Thomas G, Hawkins ES, Svensson LG| | View in PubMed
  90. THU248 Re-establishing abstinence after alcohol relapse after early transplant (LT) for alcoholic hepatitis (AH) provides survival advantage.
    George Therapondos, Brian Lee, Gene Im, John Rice, Ann Lazar, Michael R. Lucey, Ethan Weinberg, Hyosun Han, Haripriya Maddur, R. Mark Ghobrial, Christine Hsu, Oren Fix, Sheila Eswaran, Kirti Shetty, Neha Jakhete, David Victor, David Foley, Neil Mehta, Mary Rinella, Thomas Schiano, Constance Mobley, Norah Terrault| | View in PubMed
  91. Donation After Circulatory Death Is Associated With Similar Posttransplant Survival in All but the Highest-Risk Hepatocellular Carcinoma Patients.
    Silverstein J, Roll G, Dodge JL, Grab JD, Yao FY, Mehta N| | View in PubMed
  92. Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic.
    Mehta N, Parikh ND, Kelley RK, Hameed B, Singal AG| | View in PubMed
  93. Incidence of Stress Cardiomyopathy During the Coronavirus Disease 2019 Pandemic.
    Jabri A, Kalra A, Kumar A, Alameh A, Adroja S, Bashir H, Nowacki AS, Shah R, Khubber S, Kanaa'N A, Hedrick DP, Sleik KM, Mehta N, Chung MK, Khot UN, Kapadia SR, Puri R, Reed GW| | View in PubMed
  94. Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference.
    Mehta N, Bhangui P, Yao FY, Mazzaferro V, Toso C, Akamatsu N, Durand F, Ijzermans J, Polak W, Zheng S, Roberts JP, Sapisochin G, Hibi T, Kwan NM, Ghobrial M, Soin A| | View in PubMed
  95. Shorter Height Is Associated With Lower Probability of Liver Transplantation in Patients With Hepatocellular Carcinoma.
    Lee E, Sarkar M, Dodge J, Kohi M, Mehta N| | View in PubMed
  96. Unfair Advantages for Hepatocellular Carcinoma Patients Listed for Liver Transplant in Short-Wait Regions Following 2015 Hepatocellular Carcinoma Policy Change.
    Brondfield MN, Dodge JL, Hirose R, Heimbach J, Yao FY, Mehta N| | View in PubMed
  97. Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion - a multi-center retrospective cohort study.
    Assalino M, Terraz S, Grat M, Lai Q, Vachharajani N, Gringeri E, Bongini MA, Kulik L, Tabrizian P, Agopian V, Mehta N, Brustia R, Vitali GC, Andres A, Berney T, Mazzaferro V, Compagnon P, Majno P, Cillo U, Chapman W, Zieniewicz K, Scatton O, Toso C| | View in PubMed
  98. Hepatocellular Carcinoma-How to Determine Therapeutic Options.
    Mehta N| | View in PubMed
  99. Differential Impact of Age Among Liver Transplant Candidates With and Without Hepatocellular Carcinoma.
    Cullaro G, Rubin JB, Mehta N, Lai JC| | View in PubMed
  100. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time.
    Mehta N, Dodge JL, Grab JD, Yao FY| | View in PubMed
  101. REPLY.
    Mehta N, Dodge JL, Yao FY| | View in PubMed
  102. Comparison of Liver Transplant Wait-List Outcomes Among Patients With Hepatocellular Carcinoma With Public vs Private Medical Insurance.
    Gutin L, Yao F, Dodge JL, Grab J, Mehta N| | View in PubMed
  103. Using Standardized Checklists Increase the Completion Rate of Critical Actions in an Evacuation from the Operating Room: A Randomized Controlled Simulation Study.
    Acar YA, Mehta N, Rich MA, Yilmaz BK, Careskey M, Generoso J, Fidler R, Hirsch J| | View in PubMed
  104. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma.
    Singal AG, Rich NE, Mehta N, Branch AD, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Ioannou GN, Huang A, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Kagan S, Gopal P, Wong R, Parikh ND, Murphy CC| | View in PubMed
  105. Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma.
    Rich NE, Yang JD, Perumalswami PV, Alkhouri N, Jackson W, Parikh ND, Mehta N, Salgia R, Duarte-Rojo A, Kulik L, Rakoski M, Said A, Oloruntoba O, Ioannou GN, Hoteit MA, Moon AM, Rangnekar AS, Eswaran SL, Zheng E, Jou JH, Hanje J, Pillai A, Hernaez R, Wong R, Scaglione S, Samant H, Kapuria D, Chandna S, Rosenblatt R, Ajmera V, Frenette CT, Satapathy SK, Mantry P, Jalal P, John BV, Fix OK, Leise M, Lindenmeyer CC, Flores A, Patel N, Jiang ZG, Latt N, Dhanasekaran R, Odewole M, Kagan S, Marrero JA, Singal AG| | View in PubMed
  106. Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol.
    Sinha J, Mehta N, Dodge JL, Poltavskiy E, Roberts J, Yao F| | View in PubMed
  107. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation.
    Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY| | View in PubMed
  108. PS-206-Patterns and predictors of alcohol use after early liver transplant for alcoholic hepatitis.
    Brian Lee, Mary Rinella, Gene Im, John Rice, Oren Fix, George Therapondos, Hyosun Han, David Victor, Ethan Weinberg, Cristine Hsu, Michael Voigt, Haripriya Maddur, Sheila Eswaran, David Foley, R. Mark Ghobrial, Lisanne Dinges, Jennifer Dodge, Neil Mehta, Michael R. Lucey, Norah Terrault| | View in PubMed
  109. A Curriculum for Diagnostic Reasoning: JGIM's Exercises in Clinical Reasoning.
    Subramanian A, Connor DM, Berger G, Lessing JN, Mehta N, Manesh R, Kohlwes J| | View in PubMed
  110. What Are the Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma?
    Mehta N, Yao FY| | View in PubMed
  111. Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes.
    Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY| | View in PubMed
  112. Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the A-VENA Criteria.
    Sherman CB, Behr S, Dodge JL, Roberts JP, Yao FY, Mehta N| | View in PubMed
  113. The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation.
    Lee DD, Samoylova M, Mehta N, Musto KR, Roberts JP, Yao FY, Harnois DM| | View in PubMed
  114. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.
    Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Noureddine W, Ho C, Konjeti VR, Dao A, Nelson K, Delarosa K, Rahim U, Mavuram M, Xie JJ, Murphy CC, Parikh ND| | View in PubMed
  115. Screening for Hepatocellular Carcinoma to Improve Cancer-Related Mortality: Looking Behind When We Should Be Looking Ahead.
    Mehta N, Monto A, Yao FY| | View in PubMed
  116. Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation.
    Goldaracena N, Mehta N, Scalera I, Sposito C, Atenafu EG, Yao FY, Muiesan P, Mazzaferro V, Sapisochin G| | View in PubMed
  117. Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation.
    Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY| | View in PubMed
  118. Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma.
    Samoylova ML, Mehta N, Roberts JP, Yao FY| | View in PubMed
  119. A Point-based Histologic Scoring System for Hepatocellular Carcinoma Can Stratify Risk of Posttransplant Tumor Recurrence.
    Roberts DE, Kakar S, Mehta N, Gill RM| | View in PubMed
  120. Cardiac MRI T2* in Liver Transplant Candidates: Application and Performance of a Novel Imaging Technique to Identify Patients at Risk for Poor Posttransplant Cardiac Outcomes.
    Lewin SM, Kallianos K, Nevah MI, Zhao S, Fix OK, Brooks GC, De Marco T, Qasim AN, Ordovas KG, Mehta N| | View in PubMed
  121. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.
    Huang AC, Mehta N, Dodge JL, Yao FY, Terrault NA| | View in PubMed
  122. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
    Giard JM, Mehta N, Dodge JL, Roberts JP, Yao FY| | View in PubMed
  123. Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis.
    Lee BP, Mehta N, Platt L, Gurakar A, Rice JP, Lucey MR, Im GY, Therapondos G, Han H, Victor DW, Fix OK, Dinges L, Dronamraju D, Hsu C, Voigt MD, Rinella ME, Maddur H, Eswaran S, Hause J, Foley D, Ghobrial RM, Dodge JL, Li Z, Terrault NA| | View in PubMed
  124. Abstract No. 522 Outcomes of TACE for hepatocellular carcinoma in patients with HIV infection.
    E. Phillips, R. Kohlbrenner, A. True-Yasaki, N. Fidelman, A. Taylor, E. Lehrman, M. Kohi, K. Kolli, R. Kerlan, N. Mehta| | View in PubMed
  125. Abstract No. 525 Liver transplantation rates for hepatocellular carcinoma: is there a sex-related difference?.
    M. Kohi, M. Sarka, J. Dodge, J. Roberts, N. Terrault, N. Mehta| | View in PubMed
  126. Liver Transplantation for NASH-Related Hepatocellular Carcinoma Versus Non-NASH Etiologies of Hepatocellular Carcinoma.
    Sadler EM, Mehta N, Bhat M, Ghanekar A, Greig PD, Grant DR, Yao F, Sapisochin G| | View in PubMed
  127. SAT-448 Higher early post-liver transplant mortality in recipients with severe alcoholic hepatitis versus alcoholic cirrhosis.
    B. Lee, G. Im, J. Dodge, M. Voigt, J. Rice, M.R. Lucey, D. Foley, L. Platt, A. Gurakar, N. Mehta, G. Therapondos, H. Han, D. Victor, O. Fix, L. Dinges, D. Dronamraju, C. Hsu, M. Rinella, H. Maddur, S. Eswaran, J. Hause, R.M. Ghobrial, Z. Li, N. Terrault| | View in PubMed
  128. Living donor liver transplantation for hepatocellular carcinoma: To expand (beyond Milan) or downstage (to Milan)?
    Mehta N, Yao FY| | View in PubMed
  129. Hilar cholangiocarcinoma associated with immunoglobulin G4-positive plasma cells and elevated serum immunoglobulin G4 levels.
    Azeem N, Ajmera V, Hameed B, Mehta N| | View in PubMed
  130. Interventions to improve the mechanical ventilation fidelity of the Laerdal SimMan® 3G simulation mannequin.
    Mehta NJ, Latoures R, Stechert MM, Fidler RL, Hirsch J| | View in PubMed
  131. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database.
    Mehta N, Dodge JL, Roberts JP, Yao FY| | View in PubMed
  132. Con: Treating hepatitis C virus With direct-acting antivirals: Fear not the perceived threat of hepatocellular carcinoma.
    Mehta N, Yao FY| | View in PubMed
  133. International Differences in the Risk of Death from Smoking and Obesity: The Case of the United States and Finland.
    Mehta N, Elo I, Stenholm S, Aromaa A, Heliövaara M, Koskinen S| | View in PubMed
  134. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study.
    Mehta N, Guy J, Frenette CT, Dodge JL, Osorio RW, Minteer WB, Roberts JP, Yao FY| | View in PubMed
  135. Misdiagnosis of hepatocellular carcinoma in patients receiving no local-regional therapy prior to liver transplant: An analysis of the Organ Procurement and Transplantation Network explant pathology form.
    Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY| | View in PubMed
  136. Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot".
    Mehta N, Heimbach J, Lee D, Dodge JL, Harnois D, Burns J, Sanchez W, Roberts JP, Yao FY| | View in PubMed
  137. Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma.
    Lewin SM, Mehta N, Kelley RK, Roberts JP, Yao FY, Brandman D| | View in PubMed
  138. Acute liver injury in a Glatopa-treated patient with MS.
    Sabatino JJ, Mehta NJ, Kakar S, Zamvil SS, Cree BAC| | View in PubMed
  139. Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma.
    Salazar J, Saxena V, Kahn JG, Roberts JP, Mehta N, Volk M, Lai JC| | View in PubMed
  140. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.
    Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, Burns JM, Sanchez W, Greig PD, Grant DR, Roberts JP, Yao FY| | View in PubMed
  141. Screening for hepatocellular carcinoma: What is missing?
    Mehta NJ, Celik AD, Peters MG| | View in PubMed
  142. Transarterial Radioembolization for Hepatocellular Carcinoma: Who, When… and Y(90)?
    Mehta N, Yao FY| | View in PubMed
  143. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment.
    Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, Vibert E, Cherqui D, Grant DR, Hernandez-Alejandro R, Dale CH, Cucchetti A, Pinna A, Hwang S, Lee SG, Agopian VG, Busuttil RW, Rizvi S, Heimbach JK, Montenovo M, Reyes J, Cesaretti M, Soubrane O, Reichman T, Seal J, Kim PT, Klintmalm G, Sposito C, Mazzaferro V, Dutkowski P, Clavien PA, Toso C, Majno P, Kneteman N, Saunders C, Bruix J, iCCA International Consortium| | View in PubMed
  144. Reply.
    Mehta N, Yao FY| | View in PubMed
  145. Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant.
    Sarkar M, Dodge JL, Roberts JP, Terrault N, Yao F, Mehta N| | View in PubMed
  146. Lack of benefits of mammalian target of rapamycin inhibitor in patients transplanted for hepatocellular carcinoma: Is this the end of the story?
    Mehta N, Roberts JP, Yao FY| | View in PubMed
  147. Immigrant status and cardiovascular risk over time: results from the Multi-Ethnic Study of Atherosclerosis.
    Lê-Scherban F, Albrecht SS, Bertoni A, Kandula N, Mehta N, Diez Roux AV| | View in PubMed
  148. HCC recurrence following liver tranplantation should be aggresively treated to increase patient survival.
    G. Sapisochin, N. Mehta, I. Scalera, C. Sposito, F.Y. Yao, P. Muiesan, V. Mazzaferro, D.R. Grant| | View in PubMed
  149. Hepatocellular cancer as indication for liver transplantation: pushing beyond Milan.
    Mehta N, Yao FY| | View in PubMed
  150. “Very early” intrahepatic cholangiocarcinoma may become an acceptable indication for liver transplantation. A multicenter validation study.
    G. Sapisochin, M. Facciuto, N. Mehta, E. Vibert, R. Hernandez-Alejandro, A.D. Pinna, S. Hwang, V.G. Agopian, G. Gores, J. Reyes, O. Soubrane, T. Reichman, P. Kim, C. Sposito, P.A. Clavien, C. Toso, N. Kneteman, J. Bruix| | View in PubMed
  151. Nucleos(t)ide analogs reduce the risk of hepatitis B-associated hepatocellular carcinoma: A can't miss proposition?
    Mehta N, Yao FY| | View in PubMed
  152. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing.
    Mehta N, Sarkar M, Dodge JL, Fidelman N, Roberts JP, Yao FY| | View in PubMed
  153. Minimal Transplant Survival Benefit for Hepatocellular Carcinoma: Is it Real or an Overestimation of Waitlist Life Expectancy?
    Mehta N, Heimbach J, Hirose R, Roberts JP, Yao FY| | View in PubMed
  154. Abstract 19009: The Association Between Clinical and Echocardiographic Imaging Findings and T2* in End Stage Liver Disease.
    Gabriel Brooks, Kathryn Brown, Neil Mehta, Karen Ordovas, Nevah Rubin, Elyse Foster, Atif Qasim| | View in PubMed
  155. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria.
    Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, Hirose R, Fidelman N, Kerlan RK, Roberts JP| | View in PubMed
  156. Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm.
    Samoylova ML, Dodge JL, Mehta N, Yao FY, Roberts JP| | View in PubMed
  157. Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization.
    Goel A, Mehta N, Guy J, Fidelman N, Yao F, Roberts J, Terrault N| | View in PubMed
  158. Response to letter to the editors.
    Yao FY, Hameed B, Mehta N, Roberts JP| | View in PubMed
  159. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.
    Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY| | View in PubMed
  160. Should Hepatocellular Carcinoma Patients With Multiple Tumors <2cm Be Transplanted?.
    M. Samoylova, J. Dodge, F. Yao, N. Mehta, J. Roberts| | View in PubMed
  161. Outcomes after liver transplantation for patients with hepatocellular carcinoma and a low risk of dropout from the transplant waiting list.
    Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY| | View in PubMed
  162. BMJ endgames: a new web-based BMJ/JGIM collaboration.
    Srinivasan M, Mehta N| | View in PubMed
  163. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.
    Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY| | View in PubMed
  164. Adult-Onset Fatal Neurohepatopathy in a Woman Caused by MPV17 Mutation.
    Mendelsohn BA, Mehta N, Hameed B, Pekmezci M, Packman S, Ralph J| | View in PubMed
  165. Moving past "One size (and number) fits all" in the selection of candidates with hepatocellular carcinoma for liver transplantation.
    Mehta N, Yao FY| | View in PubMed
  166. Reply: To PMID 23333661.
    Yao F, Mehta N| | View in PubMed
  167. Immunosuppression: Conventions and controversies.
    Mehta N, Hirose R| | View in PubMed
  168. Factors associated with outcomes and response to therapy in patients with infiltrative hepatocellular carcinoma.
    Mehta N, Fidelman N, Sarkar M, Yao FY| | View in PubMed
  169. 1016 Risk of Hepatic Artery and Biliary Complications in Liver Transplant Recipients Treated With Transarterial Chemoembolization.
    Neil Mehta, Aparna Goel, Karen C. Bagatelos, James L. Buxbaum, Nicholas Fidelman, John P. Roberts, Norah A. Terrault, Francis Yao, James W. Ostroff| | View in PubMed
  170. Findings on serial surveillance colonoscopy in patients with low-risk polyps on initial colonoscopy.
    Miller J, Mehta N, Feldman M, Furth E, Ginsberg GG, Yang YX, Lewis JD| | View in PubMed
  171. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment.
    Mehta N, Mauer AM, Hellman S, Haraf DJ, Cohen EE, Vokes EE, Weichselbaum RR| | View in PubMed